RA Capital Management L.P. Buys Shares of 824,582 CeriBell (NASDAQ:CBLL)

RA Capital Management L.P. bought a new stake in shares of CeriBell (NASDAQ:CBLL - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 824,582 shares of the company's stock, valued at approximately $21,340,000. RA Capital Management L.P. owned about 2.30% of CeriBell at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of CBLL. Legal & General Group Plc bought a new position in shares of CeriBell in the fourth quarter valued at $32,000. Summit Investment Advisors Inc. bought a new position in CeriBell during the fourth quarter valued at approximately $33,000. Tower Research Capital LLC TRC bought a new position in shares of CeriBell in the fourth quarter valued at approximately $37,000. PNC Financial Services Group Inc. acquired a new stake in CeriBell in the 4th quarter valued at approximately $47,000. Finally, Corebridge Financial Inc. acquired a new position in shares of CeriBell during the fourth quarter valued at about $158,000.

Insider Buying and Selling at CeriBell

In related news, CEO Xingjuan Chao sold 5,700 shares of the company's stock in a transaction on Thursday, April 17th. The shares were sold at an average price of $15.02, for a total value of $85,614.00. Following the completion of the sale, the chief executive officer now owns 746,451 shares in the company, valued at $11,211,694.02. This represents a 0.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 24,700 shares of company stock worth $372,434 over the last three months.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. LADENBURG THALM/SH SH assumed coverage on shares of CeriBell in a report on Friday, April 4th. They issued a "buy" rating and a $32.00 price target for the company. Canaccord Genuity Group reissued a "buy" rating and issued a $33.00 price target on shares of CeriBell in a report on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $32.50.

CeriBell Stock Down 2.6 %

Shares of NASDAQ CBLL traded down $0.42 during trading on Tuesday, hitting $15.76. The company had a trading volume of 209,199 shares, compared to its average volume of 270,255. CeriBell has a 12 month low of $10.01 and a 12 month high of $32.75. The company has a 50 day simple moving average of $18.67.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). The business had revenue of $18.53 million during the quarter, compared to analyst estimates of $17.55 million. Research analysts anticipate that CeriBell will post -2.46 EPS for the current year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.